Stock 002262 JIANGSU NHWA PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Jiangsu Nhwa Pharmaceutical Co., LTD

Equities

002262

CNE100000CG8

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
25.01 CNY -0.28% Intraday chart for Jiangsu Nhwa Pharmaceutical Co., LTD +7.39% -7.78%
Apr. 25 Jiangsu Nhwa Pharmaceutical Co., LTD Approves Cash Dividend for 2023 CI
Apr. 19 Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 69% by 2026.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The company's enterprise value to sales, at 3.72 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JIANGSU NHWA PHARMACEUTICAL CO., LTD Stock Jiangsu Nhwa Pharmaceutical Co., LTD
-7.78% 3.48B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 235B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 189B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 002262 Stock
  4. Ratings Jiangsu Nhwa Pharmaceutical Co., LTD